{
  "success": true,
  "issues": [
    {
      "issue_type": "missed_tick",
      "activity_id": "act_13",
      "activity_name": "Adverse Event Reporting",
      "timepoint_id": "pt_1",
      "timepoint_name": "Within 28 days prior to randomization unless specified otherwise",
      "confidence": 0.99,
      "details": "Visible 'X' mark in the 'Screening' column for 'Adverse Event Reporting' was not in the provided list."
    },
    {
      "issue_type": "missed_tick",
      "activity_id": "act_15",
      "activity_name": "EuroQol-5D (EQ-5D)",
      "timepoint_id": "pt_2",
      "timepoint_name": "Day 1b",
      "confidence": 0.8,
      "details": "Text in the 'Active Treatment Phase' column for 'EuroQol-5D (EQ-5D)' implies an assessment on Day 1 of Cycles 1 and 2."
    },
    {
      "issue_type": "missed_tick",
      "activity_id": "act_15",
      "activity_name": "EuroQol-5D (EQ-5D)",
      "timepoint_id": "pt_4",
      "timepoint_name": "Day 1",
      "confidence": 0.8,
      "details": "Text in the 'Active Treatment Phase' column for 'EuroQol-5D (EQ-5D)' implies an assessment on Day 1 of subsequent cycles."
    },
    {
      "issue_type": "missed_tick",
      "activity_id": "act_16",
      "activity_name": "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)",
      "timepoint_id": "pt_2",
      "timepoint_name": "Day 1b",
      "confidence": 0.8,
      "details": "Text in the 'Active Treatment Phase' column for 'EORTC-QLQ-C30' implies an assessment on Day 1 of Cycles 1 and 2."
    },
    {
      "issue_type": "missed_tick",
      "activity_id": "act_16",
      "activity_name": "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)",
      "timepoint_id": "pt_4",
      "timepoint_name": "Day 1",
      "confidence": 0.8,
      "details": "Text in the 'Active Treatment Phase' column for 'EORTC-QLQ-C30' implies an assessment on Day 1 of subsequent cycles."
    },
    {
      "issue_type": "missed_tick",
      "activity_id": "act_17",
      "activity_name": "European Organisation for Research and Treatment of Cancer Breast Cancer Module (EORTC-QLQ-BR23)",
      "timepoint_id": "pt_2",
      "timepoint_name": "Day 1b",
      "confidence": 0.8,
      "details": "Text in the 'Active Treatment Phase' column for 'EORTC-QLQ-BR23' implies an assessment on Day 1 of Cycles 1 and 2."
    },
    {
      "issue_type": "missed_tick",
      "activity_id": "act_17",
      "activity_name": "European Organisation for Research and Treatment of Cancer Breast Cancer Module (EORTC-QLQ-BR23)",
      "timepoint_id": "pt_4",
      "timepoint_name": "Day 1",
      "confidence": 0.8,
      "details": "Text in the 'Active Treatment Phase' column for 'EORTC-QLQ-BR23' implies an assessment on Day 1 of subsequent cycles."
    },
    {
      "issue_type": "missed_tick",
      "activity_id": "act_20",
      "activity_name": "Fulvestrant (both treatment arms)",
      "timepoint_id": "pt_2",
      "timepoint_name": "Day 1b",
      "confidence": 0.95,
      "details": "Arrow mark for 'Fulvestrant' indicates activity during Day 1 of Cycles 1 and 2."
    },
    {
      "issue_type": "missed_tick",
      "activity_id": "act_20",
      "activity_name": "Fulvestrant (both treatment arms)",
      "timepoint_id": "pt_3",
      "timepoint_name": "Day 15",
      "confidence": 0.95,
      "details": "Arrow mark and text for 'Fulvestrant' indicate activity on Day 15 of Cycle 1."
    },
    {
      "issue_type": "missed_tick",
      "activity_id": "act_20",
      "activity_name": "Fulvestrant (both treatment arms)",
      "timepoint_id": "pt_4",
      "timepoint_name": "Day 1",
      "confidence": 0.95,
      "details": "Arrow mark for 'Fulvestrant' indicates activity during Day 1 of Cycles >=3."
    },
    {
      "issue_type": "missed_tick",
      "activity_id": "act_21",
      "activity_name": "Palbociclib or placebo (Arm A only)",
      "timepoint_id": "pt_2",
      "timepoint_name": "Day 1b",
      "confidence": 0.95,
      "details": "Arrow mark for 'Palbociclib or placebo' indicates activity during Day 1 of Cycles 1 and 2."
    },
    {
      "issue_type": "missed_tick",
      "activity_id": "act_21",
      "activity_name": "Palbociclib or placebo (Arm A only)",
      "timepoint_id": "pt_3",
      "timepoint_name": "Day 15",
      "confidence": 0.95,
      "details": "Arrow mark for 'Palbociclib or placebo' indicates activity during Day 15 of Cycles 1 and 2."
    },
    {
      "issue_type": "missed_tick",
      "activity_id": "act_21",
      "activity_name": "Palbociclib or placebo (Arm A only)",
      "timepoint_id": "pt_4",
      "timepoint_name": "Day 1",
      "confidence": 0.95,
      "details": "Arrow mark for 'Palbociclib or placebo' indicates activity during Day 1 of Cycles >=3."
    },
    {
      "issue_type": "missed_tick",
      "activity_id": "act_22",
      "activity_name": "For pre-/peri-menopausal patients only: Goserelin (both treatment arms, if applicable)",
      "timepoint_id": "pt_1",
      "timepoint_name": "Within 28 days prior to randomization unless specified otherwise",
      "confidence": 0.8,
      "details": "Text for 'Goserelin' indicates 'SC administration at least 4 weeks before study treatment start', corresponding to the Screening period."
    },
    {
      "issue_type": "missed_tick",
      "activity_id": "act_22",
      "activity_name": "For pre-/peri-menopausal patients only: Goserelin (both treatment arms, if applicable)",
      "timepoint_id": "pt_2",
      "timepoint_name": "Day 1b",
      "confidence": 0.95,
      "details": "Arrow mark for 'Goserelin' indicates activity during Day 1 of Cycles 1 and 2."
    },
    {
      "issue_type": "missed_tick",
      "activity_id": "act_22",
      "activity_name": "For pre-/peri-menopausal patients only: Goserelin (both treatment arms, if applicable)",
      "timepoint_id": "pt_4",
      "timepoint_name": "Day 1",
      "confidence": 0.95,
      "details": "Arrow mark for 'Goserelin' indicates activity during Day 1 of Cycles >=3."
    }
  ],
  "confirmed_ticks": 42,
  "total_ticks_checked": 42,
  "hallucination_count": 0,
  "missed_count": 16,
  "model_used": "gemini-2.5-pro",
  "error": null
}